Curanex Pharmaceuticals (CURX) Q4 2025 earnings summary

Executive summary

• Completed IPO in August 2025, raising $15M, with an additional $2.25M from over-allotment; shares listed on Nasdaq under CURX.

• Focused on developing Phyto-N, a botanical drug candidate for inflammatory diseases, with IND submission for ulcerative colitis targeted for Q4 2026.

• No revenue generated in 2025; business model anticipates future revenue from product sales, licensing, and collaborations post-approval.

• Expanded R&D activities post-IPO, advancing preclinical and IND-enabling studies for multiple indications.

Financial highlights

• Net loss of $4.2M for 2025, up from $0.36M in 2024, driven by increased R&D and G&A expenses.

• R&D expenses rose to $3.0M in 2025 from $0.07M in 2024 due to expanded preclinical studies.

• G&A expenses increased to $1.25M in 2025 from $0.29M in 2024, reflecting higher payroll and public company costs.

• Cash and equivalents at year-end 2025 were $5.0M, up from $0.15M in 2024, primarily from IPO proceeds.

• No revenue recognized in 2025 or 2024; future revenue dependent on successful product development and commercialization.

Outlook and guidance

• Existing cash expected to fund operations for at least 12 months from the report date.

• Plans to submit IND for Phyto-N in ulcerative colitis in Q4 2026, with Phase I trial initiation in Australia.

• Additional capital may be required for further clinical development and expansion.